ES2184869T3 - Vacuna sub-unitaria contra la infeccion por flavivirus. - Google Patents

Vacuna sub-unitaria contra la infeccion por flavivirus.

Info

Publication number
ES2184869T3
ES2184869T3 ES96917828T ES96917828T ES2184869T3 ES 2184869 T3 ES2184869 T3 ES 2184869T3 ES 96917828 T ES96917828 T ES 96917828T ES 96917828 T ES96917828 T ES 96917828T ES 2184869 T3 ES2184869 T3 ES 2184869T3
Authority
ES
Spain
Prior art keywords
flavivirus
sub
vaccine against
against infection
unit vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96917828T
Other languages
English (en)
Inventor
John M Ivy
Eileen Nakano
David Clements
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hawaii Biotech Inc
Original Assignee
Hawaii Biotechnology Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hawaii Biotechnology Group Inc filed Critical Hawaii Biotechnology Group Inc
Application granted granted Critical
Publication of ES2184869T3 publication Critical patent/ES2184869T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION PRESENTA VACUNAS CAPACES DE DESENCADENAR LA PRODUCCION DE ANTICUERPOS NEUTRALIZANTES CONTRA FLAVIVIRUS, QUE CONTIENEN, COMO PRINCIPIO ACTIVO, UNA PROTEINA DE LA CUBIERTA SEGREGADA PRODUCIDA POR TECNICAS RECOMBINANTES O UNA SUBUNIDAD. EN LAS REALIZACIONES QUE SE PRESENTAN, SE SEGREGAN EL DOMINIO B O EL 60-80 % DE LAS PORCIONES N - TERMINAL DE LA PROTEINA DE LA CUBIERTA (E) DEL VIRUS DEL DENGUE. EL PRODUCTO SEGREGADO PUEDE PURIFICARSE Y PREPARARSE FACILMENTE COMO VACUNA.
ES96917828T 1995-05-24 1996-05-24 Vacuna sub-unitaria contra la infeccion por flavivirus. Expired - Lifetime ES2184869T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44873495A 1995-05-24 1995-05-24
US48880795A 1995-06-07 1995-06-07
US50046995A 1995-07-10 1995-07-10

Publications (1)

Publication Number Publication Date
ES2184869T3 true ES2184869T3 (es) 2003-04-16

Family

ID=27412379

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96917828T Expired - Lifetime ES2184869T3 (es) 1995-05-24 1996-05-24 Vacuna sub-unitaria contra la infeccion por flavivirus.

Country Status (10)

Country Link
US (1) US6165477A (es)
EP (1) EP0836482B1 (es)
AT (1) ATE227584T1 (es)
AU (1) AU716676B2 (es)
CA (1) CA2224724C (es)
DE (1) DE69624815T2 (es)
DK (1) DK0836482T3 (es)
ES (1) ES2184869T3 (es)
PT (1) PT836482E (es)
WO (1) WO1996037221A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074865A (en) 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
CU22666A1 (es) * 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
KR20010022452A (ko) 1997-07-31 2001-03-15 추후제출 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신
AU2002300271B8 (en) * 1997-07-31 2006-08-10 Hawaii Biotech, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
FR2767324B1 (fr) * 1997-08-14 2001-04-06 Pasteur Institut Utilisation de proteines d'enveloppe recombinantes pour le diagnostic du virus de la dengue
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US7417136B1 (en) 1998-06-04 2008-08-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
CA2941182A1 (en) 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
ATE375169T1 (de) * 2000-04-14 2007-10-15 Intercell Ag Modifizierte peptide enthaltende pharmazeutische präparationen
EP1326625A4 (en) * 2000-09-13 2005-05-04 Hawaii Biotech Inc IMMUNOGENIC COMPOSITION OF HEPATITIS C AND METHODS FOR ITS USE
CA2440593A1 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
WO2003060088A2 (en) * 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
EP1572941A4 (en) 2002-02-26 2009-03-18 Maxygen Inc NEW FLAVIVIRUS ANTIGENES
WO2004016586A2 (en) * 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
AU2003301804A1 (en) * 2002-11-05 2004-06-07 Institut National De La Sante Et De La Recherche Medicale Dc-sign blockers and their use for preventing or treating viral infections.
US20040213808A1 (en) * 2002-12-11 2004-10-28 Michael Lieberman Recombinant vaccine against flavivirus infection
US20050287170A1 (en) * 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
EA010056B1 (ru) * 2003-10-10 2008-06-30 Паудерджект Вэксинс, Инк. Конструкции нуклеиновых кислот
US20070269461A1 (en) * 2004-01-04 2007-11-22 Sudhanshu Vrati Recombinant Vaccine Against Japanese Encephalitis Virus (Jev) Infection and a Method Thereof
US8900644B2 (en) * 2004-12-22 2014-12-02 Colgate-Palmolive Company Oral care compositions containing compounds from magnolia and hops extracts
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CN101909635B (zh) * 2008-01-11 2014-09-17 Vgx药品有限责任公司 针对多种登革病毒亚型的新颖疫苗
WO2010141084A2 (en) 2009-05-31 2010-12-09 Hawaii Biotech, Inc. Recombinant subunit west nile virus vaccine for protections of human subjects
WO2011026139A1 (en) 2009-08-31 2011-03-03 Gen-Probe Incorporated Dengue virus assay
WO2012027473A2 (en) * 2010-08-24 2012-03-01 The University Of North Carolina At Chapel Hill Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
WO2012154202A1 (en) 2010-10-29 2012-11-15 Merck Sharp & Dohme Corp. Recombinant subunit dengue virus vaccine
CA3177572C (en) 2013-03-15 2026-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
AU2017301918B2 (en) * 2016-07-27 2022-07-14 Hawaii Biotech Inc. Optimized Zika virus envelope gene and expression thereof
CN112912106A (zh) 2018-09-05 2021-06-04 武田疫苗股份有限公司 登革热疫苗单位剂量及其施用
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
US5013652A (en) * 1986-10-14 1991-05-07 Genex Corporation Composite yeast vectors
IL91304A0 (en) * 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
FR2665710A1 (fr) * 1990-08-10 1992-02-14 Pasteur Institut Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques.
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
WO1992003161A1 (en) * 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins

Also Published As

Publication number Publication date
AU716676B2 (en) 2000-03-02
DK0836482T3 (da) 2003-02-17
DE69624815D1 (de) 2002-12-19
CA2224724A1 (en) 1996-11-28
US6165477A (en) 2000-12-26
AU6023996A (en) 1996-12-11
CA2224724C (en) 2007-12-04
EP0836482A1 (en) 1998-04-22
WO1996037221A1 (en) 1996-11-28
EP0836482B1 (en) 2002-11-13
DE69624815T2 (de) 2003-07-10
ATE227584T1 (de) 2002-11-15
EP0836482A4 (en) 1999-09-01
PT836482E (pt) 2003-02-28

Similar Documents

Publication Publication Date Title
ES2190799T3 (es) Inmunogenos peptidicos para vacunacion y tratamiento de la alergia.
ES2156110T3 (es) Analogos de sub-unidades de toxina del colera derivados de adn recombinante.
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ES2187798T3 (es) Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento.
DE60125708D1 (de) Zusammensetzung zur topischen Anwendung
CA2224724A1 (en) Subunit vaccine against flavivirus infection
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
MXPA05009580A (es) Vacuna contra el virus de la influenza.
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
BR0109346A (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
DE60024100D1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
BR0108499A (pt) Agente terapêutico para hepatite c
BR0109997A (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
ES2078971T3 (es) Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas.
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
CY1105008T1 (el) Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης
KR100725637B1 (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein
EA200100700A1 (ru) Гены и белки и их применение
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
BR9808226A (pt) Coronavìrus respiratório bovino como uma vacina
ES2058100T3 (es) Vacuna combinada.